(1-tritylpiperidin-2-yl)methanol | 1426532-69-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: (1-tritylpiperidin-2-yl)methanol
• 英文别名: 1-Tritylpiperidine-2-carbaldehyde
• CAS: 1426532-69-5
• 化学式: C₂₅H₂₅NO
• 分子量: 355.48
• InChiKey: VXDMKPLCCVHEHK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2,4-二溴喹啉 、 (1-tritylpiperidin-2-yl)methanol 在 lithium chloro-isopropyl-magnesium chloride 作用下， 以 四氢呋喃 为溶剂， 反应 14.0h， 生成 (R)-(2-bromoquinolin-4-yl)[(2S)-1-(triphenylmethyl)piperidin-2-yl]methanol 、 (S)-(2-bromoquinolin-4-yl)((R)-1-tritylpiperidin-2-yl)methanol
  参考文献：
  名称：

  Development of Quinoline-Based Disruptors of Biofilm Formation Against Vibrio cholerae

  摘要：

  Biofilm formation is a major cause of bacterial persistence in nosocomial infections, leading to extended treatment times and increased rates of morbidity and mortality. Despite this, there are currently no biofilm inhibitors approved for clinical use. The synthesis and biological evaluation of a library of amino alcohol quinolines as lead compounds for the disruption of biofilm formation in Vibrio cholerae is now reported. Application of selective metal-halogen exchange chemistry installed both stereocenters in one step, to afford a simpler scaffold than the initial lead molecule, with an EC50 < 10 mu M.

  DOI：

  10.1021/ol400150z
• 作为产物：
  描述：

  methyl 1-tritylpiperidine-2-carboxylate 在 lithium aluminium tetrahydride 、 草酰氯 、 二甲基亚砜 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 22.0h， 生成 (1-tritylpiperidin-2-yl)methanol
  参考文献：
  名称：

  Development of Quinoline-Based Disruptors of Biofilm Formation Against Vibrio cholerae

  摘要：

  Biofilm formation is a major cause of bacterial persistence in nosocomial infections, leading to extended treatment times and increased rates of morbidity and mortality. Despite this, there are currently no biofilm inhibitors approved for clinical use. The synthesis and biological evaluation of a library of amino alcohol quinolines as lead compounds for the disruption of biofilm formation in Vibrio cholerae is now reported. Application of selective metal-halogen exchange chemistry installed both stereocenters in one step, to afford a simpler scaffold than the initial lead molecule, with an EC50 < 10 mu M.

  DOI：

  10.1021/ol400150z

文献信息

• Therapeutic use of isomeric forms of 2-(4-chlorophenyl)quinolin-4-yl)(piperidin-2-yl)methanol
  申请人：Glionova AB

  公开号：EP3064205A1

  公开（公告）日：2016-09-07

  The present invention relates to certain isomeric forms of the 2,4-disubstituted quinoline derivative Vacquinol-1 (NSC13316, (2-(4-chlorophenyl)quinolin-4-yl)(piperidin-2-yl)methanol), for use the in treatment of systemic cancer, as well as pharmaceutical compositions comprising said isomeric forms of the 2,4-disubstituted quinoline derivative Vacquinol-1 for the intended use.

  本发明涉及2,4-二取代喹啉衍生物Vacquinol-1（NSC13316，（2-（4-氯苯基）喹啉-4-基）（哌啶-2-基）甲醇）的某些同分异构体形式，用于治疗全身性癌症，以及包含所述2,4-二取代喹啉衍生物Vacquinol-1的同分异构体形式的制药组合物，用于所述治疗。
• COMPOUNDS AND USE FOR TREATING CANCER
  申请人：Glionova AB

  公开号：EP3043801A2

  公开（公告）日：2016-07-20
• [EN] THERAPEUTIC USE OF ISOMERIC FORMS OF 2-(4-CHLOROPHENYL)QUINOLIN-4-YL)(PIPERIDIN-2-YL)METHANOL<br/>[FR] UTILISATION THÉRAPEUTIQUE DE FORMES ISOMÉRIQUES DU 2-(4-CHLOROPHÉNYL)QUINOLINE-4-YL)(PIPÉRIDINE-2-YL)MÉTHANOL
  申请人：GLIONOVA AB

  公开号：WO2016144241A1

  公开（公告）日：2016-09-15

  The present invention relates to certain isomeric forms of the 2,4-disubstituted quinoline derivative Vacquinol-1(NSC13316, (2-(4-chlorophenyl)quinolin-4- yl)(piperidin-2-yl)methanol), for use the in treatment of systemic cancer, as well as pharmaceutical compositions comprising said isomeric forms of the 2,4-disubstituted quinoline derivative Vacquinol-1 for the intended use.